Johnson & Johnson said it is buying Crucell N.V. for about $2.41 billion in a move that will boost the American health care company's vaccine business.
Thermo Fisher Scientific Inc. has introduced the Nunclon Vita stem cell culture surface. The energy-treated polystyrene surface enables direct attachment, colony formation, and growth of human embryonic stem cells and induced pluripotent stem cells.
GE Healthcare announces the availability of human cardiomyocytes that provide a more readily available and biologically-relevant alternative to current cell models and primary cells used in drug discovery and predictive toxicity testing.
TepoFlex biocontainers provide secure, robust fluid handling options. TepoFlex polyethylene-based biocontainers are available in 2D end-ported designs from 250 mL to 20 L and 2D face-ported designs from 5 L-200 L.
Isogenica Ltd, announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of Novabiotic’s anti-infective peptide technology platform.
Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd. to identify small molecule modulators of various protein-protein interaction targets.
Onconova Therapeutics, Inc. announced agreement with the FDA regarding an SPA for the design of a pivotal Phase 3 trial for Estybon as monotherapy in patients with myelodysplastic syndromes, diseases affecting the production of healthy blood cells.
PROLOR Biotech, Inc. announced that the FDA has granted orphan drug designation to hGH-CTP, PROLOR’s longer-acting version of human growth hormone for the treatment of growth hormone deficiency. hGH-CTP is currently in a Phase 2 clinical trial.
Researchers have discovered that children with acute lymphoid leukemia had almost twice the chance of having been exposed to three or more X-rays compared with children who did not have leukemia.
New research has found that reduced levels of brain-derived neurotrophic factor, a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with seizures that are psychological in origin.
Researchers have discovered a group of substances in the body that play a key role in controlling bone density, and on this basis they have begun development of a drug for prevention and treatment of osteoporosis and other bone disorders.
A new research study may change how sports injuries involving muscle tissue are treated, as well as how much patient monitoring is necessary when potent anti-inflammatory drugs are prescribed for a long time.
A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma, the most deadly form of brain cancer. The vaccine knocks out a growth factor that characterizes the most aggressive form of the disease.
A Pennsylvania medical devices company will pay the maximum $23 million fine for illegally testing bone cement on about 200 spinal patients, three of whom died during surgery.
Tris Pharma, Inc., has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for a generic version of UCB's Tussionex, which is used for relief of cough and upper respiratory symptoms associated with allergy or a cold.